Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ARGXBullishIndustry Newsnews

High materiality8/10

argenx positive FB102 Phase 2 results; moves to Phase 3 for celiac disease

Oct 8, 2026, 1:11 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Phase 2 results with a clear path to Phase 3 and a high-interest asset acquired recently; potential upside if Phase 3 confirms efficacy and safety; risk remains on Phase 3 outcomes and competitive dynamics.

AI summary

What happened, with direct paths to the underlying reporting

argenx announced positive Phase 2 results for FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. The primary endpoint—change in villus height-to-crypt depth at day 78—was met (p=0.0176), with supporting histologic, inflammatory, and symptomatic signals and no new safety concerns. The data, obtained after acquiring Forte Biosciences in Aug 2026, support Phase 3 development and potential broader autoimmune applications.

FB102 met primary endpoint: Vh:Cd ratio improved at day 78 (p=0.0176).
Phase 2 results show histologic, inflammatory, and symptomatic signals.
ARGX to push FB102 into Phase 3 after Forte Biosciences acquisition in Aug 2026.
FDA Fast Track designation cited; celiac disease has no approved therapies.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

argenx positive FB102 Phase 2 results; moves to Phase 3 for celiac disease

argenx Announces Positive Phase 3 ALKIVIA Topline for VYVGART Hytrulo in Autoimmune Myositis

Argenx to acquire Forte Biosciences for $2.2B, expanding CD122 pipeline

Argenx Reframes Phase 3 Myositis Readout; IMNM Upside Supports Bullish View

ARGX Gains on FDA Expansion of VYVGART Usage in Myasthenia Gravis